GENITAL WARTS TREATMENT MARKET ANALYSIS

Key Developments

• In December 2023, Padagis, a pharmaceutical company, has received U.S. FDA approval to market Podofilox Gel, the first generic version of CondyloxGel, 0.5%, in the United States. Podofilox Gel is an antimitotic medication used topically for treating anogenital warts, including external genital warts and perianal warts.
• In January 2023, Verrica Pharmaceuticals, a pharmaceutical company, announced that it received the meeting minutes from its recent Type C meeting with the FDA, held on November 6, 2023. The meeting focused on discussing the Phase 3 clinical development plan for YCANTH for the treatment of common warts. Verrica believes the meeting successfully addressed its objectives to gain FDA advice and agreement on the pivotal Phase 3 study design necessary to support an efficacy supplement for this new indication. Currently approved for molluscum contagiosum, YCANTH aims to expand its therapeutic use pending further clinical trials.